Thomson Medical Group has narrowed its losses for the 1HFY2026 period ended Dec 31, 2025, by 20.6% to $10.2 million from a loss of $12.9 million a year ago.
While the group remained in a net loss position, the narrower loss reflected lower net finance costs and steady operating performance, even as Thomson Medical sustained investments in specialist services, clinical talent and digital initiatives across its markets.
This comes on the back of a 7.0% increase in revenue to $213.1 million from $199.1 million last year. The group attribute its revenue improvement to its core businesses as it advances its long-term transformation.
Revenue growth was driven by stronger revenue intensity in Singapore, improved pricing discipline following a reduction in corporate discounts, and new revenue contributions from the Oncology Centre in Malaysia, which commenced operations in November 2024. Patient volumes in Vietnam also increased during the period, partially offset by an unfavourable foreign exchange impact from the Vietnamese Dong.
However, costs and expenses – inventories and consumbables used, staff costs, depreciation and amortisation expenses and oher operating expenses – have increased, leading to results from operating activities to decline by 9.8% y-o-y to $18.2 million.
Dr Melvin Heng, group CEO of Thomson Medical says: "Revenue growth remains the clearest indicator of whether our strategy is working, and these results show that our operating businesses are responding well to the investments we have made over the past few years."
See also: LREIT’s 1HFY2026 DPU up 3.1% y-o-y to 1.85 cents
“Importantly, this growth is coming from the areas we have been deliberately building: deeper multidisciplinary care in Singapore, specialist services such as oncology in Malaysia, and rising patient volumes in Vietnam. While we continue to invest with a long-term view, the fundamentals of the group are strengthening,” he adds.
On Feb 11, shares in Thomson Medical closed at 6.2 cents, gaining some 55% in the past 12 months.
